Cholinergic Mechanisms in Gastrointestinal Neoplasia

Natalia Sampaio Moura1, Alyssa Schledwitz1, Madeline Alizadeh2

  • 1Department of Medicine, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.

Insights

Acetylcholine receptors, both nicotinic and muscarinic, are implicated in gastrointestinal cancers. Understanding their role may lead to new prognostic and therapeutic strategies for stomach, pancreas, and colon adenocarcinomas.

Area of Science:

  • Gastroenterology
  • Molecular Biology
  • Oncology

Background:

  • Acetylcholine-activated receptors exist as nicotinic and muscarinic subtypes.
  • Both receptor types are involved in normal digestive functions.
  • Dysregulation of cholinergic signaling is linked to gastrointestinal neoplasia.

Purpose of the Study:

  • To review the classification and function of acetylcholine receptors.
  • To examine acetylcholine synthesis, release, and measurement in the GI tract.
  • To evaluate the role of acetylcholine receptors in promoting gastrointestinal cancers.

Main Methods:

  • Literature review of acetylcholine receptor classification and function.
  • Analysis of acetylcholine synthesis and release mechanisms in the GI microenvironment.
  • Critical evaluation of evidence linking cholinergic signaling to gastrointestinal neoplasia.

Main Results:

  • Acetylcholine receptors (nicotinic and muscarinic) are crucial in normal GI function.
  • Challenges exist in accurately measuring acetylcholine levels.
  • Evidence supports the role of acetylcholine receptor activation in promoting stomach, pancreas, and colon adenocarcinomas.

Conclusions:

  • Cholinergic signaling pathways are implicated in gastrointestinal cancer development.
  • Targeting acetylcholine receptors offers potential for novel cancer prognostics and therapeutics.
  • Further research is needed to fully elucidate these mechanisms for clinical application.

Related Concept Videos

Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.3K
Parasympathetic Signaling01:30

Parasympathetic Signaling

Parasympathetic signaling plays a crucial role in regulating various physiological processes. It involves the release of acetylcholine (ACh) by parasympathetic neurons, which can have localized and short-lived effects. The majority of ACh released is rapidly inactivated at the synapse by the enzyme acetylcholinesterase (AChE), which hydrolyzes Ach into choline and acetate. Additionally, the tissue cholinesterase deactivates any ACh diffusing into the surrounding tissues.
The effects of...
1.9K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
661
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.1K
Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
2.1K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
731